Rights issue and Over-Allotment Option in Isofol Medical AB (SE) — SEK 500 million

Carnegie acted as joint bookrunner in the fully guaranteed SEK 400 million rights issue and over-allotment option of approximately SEK 100 million in Isofol. Isofol is a clinical stage biotech company developing arfolitixorin to improve the efficacy of standard of care chemotherapy for advanced colorectal cancer by increasing tumor response and progression free survival.
June 2021.